| Psoriasis vulgaris
Bryhali vs Tazorac
Side-by-side clinical, coverage, and cost comparison for psoriasis vulgaris.Deep comparison between: Bryhali vs Tazorac with Prescriber.AI
AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.Safety signalsTazorac has a higher rate of injection site reactions vs Bryhali based on FDA-approved prescribing information
Coverage gaps3 major payers require step therapy for Tazorac but not Bryhali, including UnitedHealthcare
Sign up to reveal the full AI analysis
Category
Bryhali
Tazorac
At A Glance
Topical
Daily
Topical corticosteroid
Topical
Daily
Retinoid
Indications
- Psoriasis vulgaris
- Psoriasis vulgaris
- Acne Vulgaris
Dosing
Psoriasis vulgaris Apply a thin layer to affected areas once daily; do not exceed 8 weeks of treatment or approximately 50 g per week; discontinue when control is achieved; avoid occlusive dressings unless directed, and do not use on face, groin, or axillae.
Psoriasis vulgaris Apply a thin film (2 mg/cm2) of 0.05% cream once daily in the evening to psoriatic lesions only; increase to 0.1% if tolerated and medically indicated.
Acne Vulgaris Apply a thin layer (2 mg/cm2) of 0.1% cream once daily in the evening to affected facial skin areas after gentle cleansing and drying.
Contraindications
—
- Pregnancy (retinoids may cause fetal harm)
- Known hypersensitivity to any component of TAZORAC Cream
Adverse Reactions
Most common (>=1%) Upper respiratory tract infection, application site dermatitis, hyperglycemia
Most common (>=10%) Psoriasis: pruritus, erythema, burning; Acne: desquamation, dry skin, erythema, burning sensation
Serious Embryofetal toxicity, photosensitivity and risk of sunburn
Postmarketing Blister, dermatitis, urticaria, skin exfoliation, skin discoloration (hyperpigmentation or hypopigmentation), swelling at or near application sites, pain
Pharmacology
Topical corticosteroid; corticosteroids play a role in cellular signaling, immune function, inflammation, and protein regulation, though the precise mechanism of action in plaque psoriasis is unknown.
Tazarotene is a retinoid prodrug converted by esterase hydrolysis to tazarotenic acid, which binds retinoic acid receptors RAR-beta and RAR-gamma with relative selectivity and may modify gene expression in psoriatic and acne-affected skin.
Enter your patient's insuranceCheck specific coverage details for your patient.
Most Common Insurance
Anthem BCBS
Bryhali
- Covered on 5 commercial plans
- PA (0/12) · Step Therapy (6/12) · Qty limit (9/12)
No coverage data available for Tazorac.
UnitedHealthcare
Bryhali
- Covered on 4 commercial plans
- PA (0/8) · Step Therapy (0/8) · Qty limit (0/8)
No coverage data available for Tazorac.
Humana
Bryhali
- Covered on 0 commercial plans
- PA (1/3) · Step Therapy (2/3) · Qty limit (2/3)
No coverage data available for Tazorac.
Coverage data sourced from MMIT. Updated monthly.
Savings
No savings programs available for Bryhali.
No savings programs available for Tazorac.
Compare Other Drugs
Let us handle your prior authsJust enter your patient's info and we'll:
- Verify eligibility with the payer.
- Pull the right PA forms directly from the payer.
- Submit, track & send live updates to your dashboard.
Free to start · HIPAA compliant
Next Steps for Your Patient
BryhaliView full Bryhali profile
TazoracView full Tazorac profile
Clinical data sourced from FDA-approved labeling. Coverage data via MMIT. Updated monthly.